Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
amgen
5
×
biotech
life sciences
national
5
×
national blog main
national top stories
new york blog main
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
indiana blog main
indiana top stories
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
eli lilly
fda
alder biopharmaceuticals
allergan
biohaven
calcitonin gene-related peptide
eptinezumab
erenumab
fremanezumab
galcanezumab
merck
What
new
5
×
drug
class
fda
migraine
approval
drugs
medicines
nod
won
adults
advantages
allergan
amgen
approved
arguments
bar
big
bio
brings
candidates
cholesterol
commercialized
companies
competitors
decades
developed
expect
expensive
faces
financial
foe
gamble
gets
head
healthcare
hint
inhibitors
known
lowering
Language
unset
Current search:
national
×
new
×
amgen
×
@xconomy.com
4 years ago
Allergan Wins FDA Nod for First Migraine Pill in New Class of Medicines
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines